At the 2026 European Society for Medical Oncology (ESMO) Congress, Sara Lonardi, MD, presented the final overall survival (OS) analysis of the phase 3 CheckMate-8HW trial (NCT04008030), which evaluated nivolumab (Opdivo) plus ipilimumab (Yervoy) vs nivolumab monotherapy or chemotherapy in patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC).1,2
